Bioxcel Therapeutics ( (BTAI) ) has released its Q2 earnings. Here is a breakdown of the information Bioxcel Therapeutics presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience, with a focus on drug re-innovation. The company recently reported its second quarter 2025 financial results, highlighting significant developments in its clinical programs and financial performance.
In the second quarter of 2025, BioXcel Therapeutics completed its SERENITY At-Home Phase 3 trial, which aims to treat agitation in patients with bipolar disorders or schizophrenia in a home setting. The company anticipates releasing topline data from this trial in August, which could expand the market opportunity for its BXCL501 drug. Additionally, BioXcel is preparing for an FDA meeting to support a potential label expansion for IGALMI, its sublingual film formulation.
Financially, the company reported a net revenue of $120 thousand from IGALMI for the second quarter, a significant decrease from $1.1 million in the same period in 2024. The company also experienced a net loss of $19.2 million, compared to a net loss of $8.3 million in the previous year. Despite these challenges, BioXcel has strengthened its cash position with additional proceeds from its at-the-market program and warrant exercises.
Looking ahead, BioXcel Therapeutics remains focused on advancing its clinical trials and exploring new therapeutic indications for its products. The management is optimistic about the potential market expansion for BXCL501 and is committed to fulfilling its mission of providing transformative treatments for patients with neurological conditions.